GlassScriptPhysician profile
Wendy Lantz
NPI 1093466526
$1,938.84
in general payments reported to CMS, 2019-2025
22 companies · $193 in 2025
The $193 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $440 · 2023: $1,242 · 2024: $63.47 · 2025: $193.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,499.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,499.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $378.73 | 2022-2023 | |
| Amgen INC. | $202.98 | 2022-2023 | Repatha |
| Kerecis Limited | $182.59 | 2024-2025 | Kerecis Surgiclose, Kerecis Graftguide, Kerecis Omega3 Marigen |
| Bayer Healthcare Pharmaceuticals INC. | $166.66 | 2022-2023 | |
| Arthrex, INC. | $134.17 | 2023 | Arthrex |
| Edwards Lifesciences Corporation | $130.78 | 2023 | Sapien 3 Ultra Resilia |
| Smith+Nephew, INC. | $126.50 | 2022 | |
| Merck Sharp & Dohme LLC | $125.43 | 2022-2024 | Verquvo |
| Novartis Pharmaceuticals Corporation | $98.53 | 2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $74.38 | 2022-2023 | Jardiance |
| Novo Nordisk INC | $59.99 | 2022-2023 | Ozempic, Rybelsus |
| United Therapeutics Corporation | $43.77 | 2022-2023 | Orenitram, Tyvaso |
| Esperion Therapeutics, INC. | $36.62 | 2023 | Nexletol |
| Actelion Pharmaceuticals US, INC. | $30.89 | 2023 | |
| Kiniksa Pharmaceuticals, LTD. | $29.40 | 2023 | Arcalyst |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Philips North America LLC | $21.76 | 2024 | (Ck4) Mcot |
| Irhythm Technologies, INC. | $18.37 | 2023 | Zio Xt Patch |
| Davol INC. | $16.83 | 2025 | Phasix Mesh |
| Janssen Pharmaceuticals, INC | $16.62 | 2023 | Xarelto |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $16.20 | 2023 | Lifevest |
| Pacira Pharmaceuticals Incorporated | $14.51 | 2024 | Zilretta, Iovera, Exparel |
| Csl Behring | $13.13 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Wendy Lantz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.